Abstract
Introduction: Prostate cancer (PCa) risk stratification is essential in guiding therapeutic decision. Multiparametric magnetic resonance tomography (mpMRI) holds promise in the prediction of adverse pathologies (AP) after prostatectomy (RP). This study aims to identify clinical and imaging markers in the prediction of adverse pathology. Methods: Patients with PCa, diagnosed by targeted biopsy after mpMRI and undergoing RP, were included. The predictive accuracy of mpMRI for extraprostatic extension (ECE), seminal vesicle infiltration (SVI), and lymph node positivity was calculated from the final histopathology. Results: 846 patients were involved. Independent risk parameters include imaging findings such as ECE (OR 3.12), SVI (OR 2.55), and PI-RADS scoring (4: OR 2.01 and 5: OR 4.34). mpMRI parameters such as ECE, SVI, and lymph node metastases showed a high prognostic accuracy (73.28% vs. 95.35% vs. 93.38%) with moderate sensitivity compared to the final histopathology. The ROC analysis of our combined scoring system (D’Amico classification, PSA density, and MRI risk factors) improves the prediction of adverse pathology (AUC: 0.73 vs. 0.69). Conclusion: Our study supports the use of mpMRI for comprehensive pretreatment risk assessment in PCa. Due to the high accuracy of factors like ECE, SVI, and PI-RADS scoring, utilizing mpMRI data enabled accurate prediction of unfavorable pathology after RP.
Journal Section:
Research Article
References
1.
Bray
F
, Ferlay
J
, Soerjomataram
I
, Siegel
RL
, Torre
LA
, Jemal
A
. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2018
;68
(6
):394
–424
. .2.
Taitt
HE
. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location
. Am J Men’s Health
. 2018
;12
(6
):1807
–23
. .3.
Borkowetz
A
, Platzek
I
, Toma
M
, Renner
T
, Herout
R
, Baunacke
M
, et al. Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography-fusion biopsy
. BJU Int
. 2016
;118
(2
):213
–20
. .4.
Borkowetz
A
, Platzek
I
, Toma
M
, Renner
T
, Herout
R
, Baunacke
M
, et al. Evaluation of prostate imaging reporting and data system classification in the prediction of tumor aggressiveness in targeted magnetic resonance imaging/ultrasound-fusion biopsy
. Urol Int
. 2017
;99
(2
):177
–85
. .5.
Gomez-Iturriaga
A
, Casquero
F
, Pijoan
JI
, Crook
J
, Urresola
A
, Ezquerro
A
, et al. Pretreatment multiparametric magnetic resonance imaging findings are more accurate independent predictors of outcome than clinical variables in localized prostate cancer
. Int J Radiat Oncol Biol Phys
. 2018
;101
(5
):1172
–8
. .6.
Woo
S
, Han
S
, Kim
TH
, Suh
CH
, Westphalen
AC
, Hricak
H
, et al. Prognostic value of pretreatment MRI in patients with prostate cancer treated with radiation therapy: a systematic review and meta-analysis
. AJR Am J Roentgenol
. 2020
;214
(3
):597
–604
. .7.
Leyh-Bannurah
SR
, Gazdovich
S
, Budäus
L
, Zaffuto
E
, Dell’Oglio
P
, Briganti
A
, et al. Population-based external validation of the updated 2012 partin tables in contemporary north American prostate cancer patients
. Prostate
. 2017
;77
(1
):105
–13
. .8.
Zanelli
E
, Giannarini
G
, Cereser
L
, Zuiani
C
, Como
G
, Pizzolitto
S
, et al. Head-to-head comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy
. J Magn Reson Imaging
. 2019
;50
(5
):1604
–13
. .9.
Hegde
JV
, Chen
MH
, Mulkern
RV
, Fennessy
FM
, D’Amico
AV
, Tempany
CMC
. Preoperative 3-tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer
. Int J Radiat Oncol Biol Phys
. 2013
;85
(2
):e101
–7
. .10.
Barentsz
JO
, Weinreb
JC
, Verma
S
, Thoeny
HC
, Tempany
CM
, Shtern
F
, et al. Synopsis of the PI-rads v2 guidelines for multiparametric prostate magnetic resonance imaging and recommendations for use
. Eur Urol
. 2016
;69
(1
):41
–9
. .11.
Weinreb
JC
, Barentsz
JO
, Choyke
PL
, Cornud
F
, Haider
MA
, Macura
KJ
, et al. PI-RADS prostate imaging - reporting and data system: 2015, version 2
. Eur Urol
. 2016
;69
(1
):16
–40
. .12.
Hattori
S
, Kosaka
T
, Mizuno
R
, Kanao
K
, Miyajima
A
, Yasumizu
Y
, et al. Prognostic value of preoperative multiparametric magnetic resonance imaging (MRI) for predicting biochemical recurrence after radical prostatectomy
. BJU Int
. 2014
;113
(5
):741
–7
. .13.
Manceau
C
, Beauval
JB
, Lesourd
M
, Almeras
C
, Aziza
R
, Gautier
JR
, et al. MRI characteristics accurately predict biochemical recurrence after radical prostatectomy
. J Clin Med
. 2020
;9
(12
):3841
. .14.
Bommelaere
T
, Villers
A
, Puech
P
, Ploussard
G
, Labreuche
J
, Drumez
E
, et al. Risk estimation of metastatic recurrence after prostatectomy: a model using preoperative magnetic resonance imaging and targeted biopsy
. Eur Urol Open Sci
. 2022
;41
:24
–34
. .15.
Cash
H
, Maxeiner
A
, Stephan
C
, Fischer
T
, Durmus
T
, Holzmann
J
, et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy
. World J Urol
. 2016
;34
(4
):525
–32
. .16.
Ahmed
HU
, El-Shater Bosaily
A
, Brown
LC
, Gabe
R
, Kaplan
R
, Parmar
MK
, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
. Lancet
. 2017
;389
(10071
):815
–22
. .17.
Borkowetz
A
, Renner
T
, Platzek
I
, Toma
M
, Herout
R
, Baunacke
M
, et al. Evaluation of magnetic resonance imaging/ultrasound-fusion biopsy in patients with low-risk prostate cancer under active surveillance undergoing surveillance biopsy
. Urol Int
. 2018
;100
(2
):155
–63
. .18.
Ahdoot
M
, Wilbur
AR
, Reese
SE
, Lebastchi
AH
, Mehralivand
S
, Gomella
PT
, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis
. N Engl J Med
. 2020
;382
(10
):917
–28
. .19.
Radtke
JP
, Hadaschik
BA
, Wolf
MB
, Freitag
MT
, Schwab
C
, Alt
C
, et al. The impact of magnetic resonance imaging on prediction of extraprostatic extension and prostatectomy outcome in patients with low-intermediate- and high-risk prostate cancer: try to find a standard
. J Endourol
. 2015
;29
(12
):1396
–405
. .20.
Dorff
TB
, Glode
LM
. Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer
. Curr Opin Urol
. 2013
;23
(4
):366
–71
. .21.
Gandaglia
G
, Ploussard
G
, Valerio
M
, Mattei
A
, Fiori
C
, Roumiguie
M
, et al. The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy
. Eur Urol
. 2020
;77
(6
):733
–41
. .22.
Murata
Y
, Tatsugami
K
, Yoshikawa
M
, Hamaguchi
M
, Yamada
S
, Hayakawa
Y
, et al. Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer
. Int J Urol
. 2018
;25
(3
):284
–9
. .23.
Kir
G
, Arikan
EA
, Seneldir
H
, Ankarali
H
, Oznergiz
S
, Olgun
ZC
, et al. Determining the cut-off values of tumor diameter, degree of extraprostatic extension, and extent of surgical margin positivity with regard to biochemical recurrence of prostate cancer after radical prostatectomy
. Ann Diagn Pathol
. 2020
;44
:151431
. .24.
Triquell
M
, Regis
L
, Winkler
M
, Valdés
N
, Cuadras
M
, Celma
A
, et al. Multiparametric MRI for staging of prostate cancer: a multicentric analysis of predictive factors to improve identification of extracapsular extension before radical prostatectomy
. Cancers
. 2022
;14
(16
):3966
. .25.
Tamada
T
, Kido
A
, Yamamoto
A
, Takeuchi
M
, Miyaji
Y
, Moriya
T
, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-rads version 2.1
. J Magn Reson Imaging
. 2021
;53
(1
):283
–91
. .26.
Xu
L
, Zhang
G
, Shi
B
, Liu
Y
, Zou
T
, Yan
W
, et al. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer
. Cancer Imag
. 2019
;19
(1
):90
. .27.
Caglic
I
, Sushentsev
N
, Shah
N
, Warren
AY
, Lamb
BW
, Barrett
T
. Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy naïve patients
. Eur J Radiol
. 2021
;141
:109804
. .28.
Polanec
S
, Helbich
TH
, Bickel
H
, Pinker-Domenig
K
, Georg
D
, Shariat
SF
, et al. Head-to-head comparison of PI-RADS v2 and PI-RADS v1
. Eur J Radiol
. 2016
;85
(6
):1125
–31
. .29.
Schaudinn
A
, Gawlitza
J
, Mucha
S
, Linder
N
, Franz
T
, Horn
LC
, et al. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard
. Eur J Radiol
. 2019
;116
:180
–5
. .© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
